|
MYCBP2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 9.79571979087268E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.61989999192258E-09 |
| Normal-vs-Stage2 |
7.57140000029466E-07 |
| Normal-vs-Stage3 |
1.27300003871511E-09 |
| Normal-vs-Stage4 |
1.45340000035077E-08 |
| Stage1-vs-Stage2 |
3.809400E-01 |
| Stage1-vs-Stage3 |
1.670850E-01 |
| Stage1-vs-Stage4 |
1.776600E-01 |
| Stage2-vs-Stage3 |
8.999400E-01 |
| Stage2-vs-Stage4 |
7.376000E-01 |
| Stage3-vs-Stage4 |
7.992600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
4.07199829410843E-11 |
| Normal-vs-AfricanAmerican |
4.443300E-04 |
| Normal-vs-Asian |
1.71589999999888E-05 |
| Caucasian-vs-AfricanAmerican |
6.349800E-01 |
| Caucasian-vs-Asian |
6.055600E-01 |
| AfricanAmerican-vs-Asian |
9.376400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.14261941522409E-12 |
| Normal-vs-Female |
6.62940036200155E-10 |
| Male-vs-Female |
3.681800E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.96570000277063E-08 |
| Normal-vs-Age(41-60Yrs) |
2.69460009860722E-10 |
| Normal-vs-Age(61-80Yrs) |
1.73350001020367E-09 |
| Normal-vs-Age(81-100Yrs) |
2.623300E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.320400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.585190E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
4.554400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
5.354000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.602000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.397400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.953230E-01 |
| Classical-VS-Follicular |
2.023800E-03 |
| Classical-VS-Other |
5.603900E-02 |
| Classical-VS-Normal |
6.93369994753112E-09 |
| Tall-VS-Follicular |
5.241800E-01 |
| Tall-VS-Other |
2.239400E-01 |
| Tall-VS-Normal |
4.65480000000351E-06 |
| Follicular-VS-Other |
4.275600E-01 |
| Follicular-VS-Normal |
2.55739984744707E-10 |
| Other-VS-Normal |
3.762600E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.42119982449174E-10 |
| Normal-vs-N1 |
2.37200004082894E-09 |
| N0-vs-N1 |
2.180800E-01 |
|
|
